Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9463449 | 0.84 | TSHR (0.34) | TSHRALDH1A1TRPA1GABRA1GABRB2 | |
| SCHEMBL1539501 | 0.83 | ALDH1A1 (0.36) | TSHRALDH1A1TRPA1GABRA1GABRB2 | |
| SCHEMBL2219283 | 0.83 | GABRA1 (0.46) | TSHRALDH1A1TRPA1GABRA1GABRB2 | |
| SCHEMBL29426990 | 0.83 | GABRA1 (0.46) | TSHRALDH1A1TRPA1GABRA1GABRB2 | |
| SCHEMBL31158055 | 0.82 | P2RX7 (0.39) | P2RX7TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL9492902 | 0.82 | GABRA1 (0.48) | P2RX7TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL11265054 | 0.82 | P2RX7 (0.39) | P2RX7TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL11262186 | 0.82 | GABRA1 (0.43) | P2RX7TSHRALDH1A1GABRA1GABRB2 | |
| SCHEMBL28791117 | 0.81 | CYSLTR2 (0.35) | P2RX7TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3057597 | 0.80 | TSHR (0.34) | P2RX7TSHRGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| EP-2970323-B1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9670221-B2 | Furopyridines as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920183-B1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2014140077-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| CN-102268041-A | Bulk electron-enriching phosphine ligand catalyst and preparation method and use thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-5264436-A | Alpha-adrenoceptors antagonist, hypotensive agents or antidiabetic agents | BEECHAM GROUP P.L.C. (GB) | 1993-11-23 | — | — | US | disclosed |
| EP-0275639-B1 | N-SUBSTITUTED CYCLIC AMIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | disclosed |
| US-5077299-A | Glaucoma, antidepressants, anticoagulants, hypotensive agents | BEECHAM GROUP P.L.C. (GB) | 1991-12-31 | — | — | US | disclosed |
| US-4918083-A | 4,5 Dihydroimidazole compounds which have useful pharmaceutical utility | BEECHAM GROUP P.L.C. (GB) | 1990-04-17 | — | — | US | disclosed |
| EP-0275639-A1 | N-substituted cyclic amides, their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-07-27 | — | — | EP | disclosed |
| US-4338331-A | DIURETIC, SLLURETIC, HYPOTENSIVE | FARMATIS S.P.A. (IT) | 1982-07-06 | — | — | US | disclosed |
| US-4338331-A | DIURETIC, SLLURETIC, HYPOTENSIVE | FARMATIS S.P.A. (IT) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | P2RX7 2090/4885TSHR 1578/4885ALDH1A1 2234/4885 |
| US-20170313677-A1 | Isoindoline Derivatives | OPRD1, ADRA1D, DRD2 | P2RX7 624/4885TSHR 284/4885ALDH1A1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.